This Section has restricted access and is intended solely and exclusively for
If you are not a healthcare expert, you are not granted and are disallowed access to the information contained in this Section, and you may not review it.
Are you a healthcare expert?
Subscribe to the news?
You have successfully signed up!
(the communication applies to valsartan drugs produced by Teva/Actavis Company)
Every year on April 11, the whole world celebrates World Day against Parkinson's disease (on the birthday of the English scientist J. Parkinson, the first researcher of the disease).
Teva Kazakhstan participated as a benefactor in the Action of "Scandinavian Walking Wins Parkinson's Disease - Marathon of Two Capitals" which was organized by the RPO "ODR-Eurasia" and was held on 11 of April of this year in Almaty and Astana
We are pleased to announce that the Multiple Sclerosis Information Portal «For Yourself. For the freedom ", created with the support of Teva Kazakhstan, starts its work since 20 of March
The first medical forum Teva "Cardio Sphere" was hosted in Moscow on October 6-7 of 2017
Teva took part in the conference «Kaishibayev Readings» as one of the main sponsors which was on October 6-7 of 2017 and held a satellite symposium in the framework of the conference.
On the eve of the autumn-winter season of upper and lower respiratory tract infections "Antibiotic therapy: yesterday, today and tomorrow» themed conferences were held in Almaty, Astana and Karaganda on October 2-4, 2017
Master-class on the theme "Tactical solutions of antihypertensive therapy of comorbid patients" was held for general practitioners, therapists and cardiologists in Almaty on September 23 of 2017
On August 3, Teva published its financial report for the second quarter of 2017, in which, particularly, it was said that the company was cutting back operations in 45 countries.
We improve the quality and extend interaction with healthcare professionals, due to this we launch a webinar portal.
On March 4, the very first and unique online webinar was held within the "Glatiramer acetate 40 mg" symposium: Today principles and optimization of therapy for patients with remittent multiple sclerosis.
This transaction strengthens Teva's strategy, facilitates an accelerated transition to a new business model and opens up new opportunities for the company in the production of generics and specialty. The company provides medicinal products to 250 million people around the world every day.